JPH0456010B2 - - Google Patents

Info

Publication number
JPH0456010B2
JPH0456010B2 JP58095683A JP9568383A JPH0456010B2 JP H0456010 B2 JPH0456010 B2 JP H0456010B2 JP 58095683 A JP58095683 A JP 58095683A JP 9568383 A JP9568383 A JP 9568383A JP H0456010 B2 JPH0456010 B2 JP H0456010B2
Authority
JP
Japan
Prior art keywords
days
group
drug
muscle
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP58095683A
Other languages
English (en)
Japanese (ja)
Other versions
JPS59222424A (ja
Inventor
Katsutaka Nagai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsui Toatsu Chemicals Inc
Original Assignee
Mitsui Toatsu Chemicals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsui Toatsu Chemicals Inc filed Critical Mitsui Toatsu Chemicals Inc
Priority to JP58095683A priority Critical patent/JPS59222424A/ja
Publication of JPS59222424A publication Critical patent/JPS59222424A/ja
Publication of JPH0456010B2 publication Critical patent/JPH0456010B2/ja
Granted legal-status Critical Current

Links

Landscapes

  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP58095683A 1983-06-01 1983-06-01 神経障害疾患治療剤 Granted JPS59222424A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP58095683A JPS59222424A (ja) 1983-06-01 1983-06-01 神経障害疾患治療剤

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP58095683A JPS59222424A (ja) 1983-06-01 1983-06-01 神経障害疾患治療剤

Publications (2)

Publication Number Publication Date
JPS59222424A JPS59222424A (ja) 1984-12-14
JPH0456010B2 true JPH0456010B2 (enExample) 1992-09-07

Family

ID=14144289

Family Applications (1)

Application Number Title Priority Date Filing Date
JP58095683A Granted JPS59222424A (ja) 1983-06-01 1983-06-01 神経障害疾患治療剤

Country Status (1)

Country Link
JP (1) JPS59222424A (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2727864B1 (fr) * 1994-12-12 1997-04-04 Synthelabo Utilisation des ligands des sites de liaison peripherique pour les benzodiazepines pour la preparation de medicaments utiles dans le traitement des neuropathies peripheriques
DE19958684A1 (de) * 1999-12-06 2001-06-07 Knoll Ag Verwendung von GD3-Synthase-Inhibitoren zur Behandlung neuropathologischer Störungen und Verfahren zur Identifizierung von GD3-Synthase-Inhibitoren
CN103040976B (zh) * 2012-12-31 2014-01-15 刘建贞 一种促进面神经损伤外科吻合术后康复的药物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1046051B (it) * 1975-08-13 1980-06-30 Fidia Spa Nuova applicazione terapeutica dei gangliosidi e procedimento per la loro estrazione

Also Published As

Publication number Publication date
JPS59222424A (ja) 1984-12-14

Similar Documents

Publication Publication Date Title
DE69233643T2 (de) Verwendung von Antizytokin-enthaltenden pharmazeutischen Zusammensetzungen zur Therapie von multipler Sklerose
US4476119A (en) Method for preparing ganglioside derivatives and use thereof in pharmaceutical compositions
DE69324859T2 (de) Verwendung von Lipid-gebundener Glykoaminoglykanen zur Behandlung der rheumatoider Arthritis
DE3854297T2 (de) Nucleoside und nucleotide mit antiviraler, antitumoraler, antimetastatischer sowie immunstimulierender wirkung.
EP0148045B1 (en) Pharmaceutical compositions and method for preparing phosphatidylserine compositions useful in treating central nervous system disorders without effects on blood coagulation
CN1794999B (zh) 神经损伤治疗剂
US4707469A (en) Gangliosides mixture, useful as a therapeutical tool for eliminating painful effects or peripheral neuropathies
DE69019388T2 (de) Verwendung von N-Methyl-Sphingosin als Zell-Wachstums-Inhibitor.
US5183807A (en) Use of monosialoganglioside gm, to prevent the development of tolerance to the analgesic effect of morphine and related drugs
DE3830271A1 (de) Mittel mit immunsuppressiver wirkung
JPH0456010B2 (enExample)
DE4341161A1 (de) Membrangängiger Wirkstoff zur Störung der DNA-Biosynthese
DE60109279T2 (de) Pharmazeutische zusammensetzungen mit oligosacchariden und deren herstellung
US20230136569A1 (en) Use of nmn to reduce immunodepression and immunosenescence
JPS60252416A (ja) Ｃｄｐコリン組成物
JPS6327434A (ja) ガングリオシドを含有する医薬
South-East European Oncology Group (SEEOG) et al. Phase II study of 4′-epi-doxorubicin in patients with untreated, extensive small cell lung cancer
US5916884A (en) Compositions containing a mixture of phosphorus compounds and alkylglycerols
Russo Jr Valproate‐induced stomatitis
JPS6368526A (ja) シアリルグリセライドからなる神経障害疾患治療剤
US20020173489A1 (en) Compositions containing a mixture of phosphorous compounds and alkylglycerols
DE69019148T2 (de) D-asparaginsäure-beta-hydroxamat zur behandlung viraler infektionen und tumoren.
Gillies et al. Succinylcholine as a Relaxant in Abdominal Surgery.
DE68909399T2 (de) Verwendung von Gangliosiden zur Behandlung der Dysfunktion des autonomen Nervensystems bei der Chagas-Krankheit.
EP4684014A1 (en) Methods for treating nervous system disorders